Increasing peptide complexity, broader portfolio diversity and rapidly changing volume requirements are placing growing constraints on conventional peptide manufacturing models. At the same time, manufacturers are expected to integrate new technologies, improve sustainability and accelerate development timelines without compromising robustness or regulatory compliance.
This webinar examines how modular process and facility design can be applied to modern peptide manufacturing to enable scalable, flexible and innovation‑ready production platforms. The discussion will focus on the use of standardized manufacturing modules for critical unit operations that can be configured to specific peptide synthesis strategies, including SPPS‑based, hybrid and intensified processes.
Using a modular expansion in Malmö as a concrete industrial case study, the speakers will illustrate how a modular architecture supports scale‑out concepts, simplifies technology transfer and enables the progressive integration of innovation such as process intensification, automation and sustainability‑driven sub‑modules. The session will also address the impact of modularity on speed to IND, asset utilization and long‑term manufacturing resilience.
Register for this webinar to learn how peptide manufacturing can be improved through modular design, faster scale-up and more efficient technology transfer.
Speakers
Christelle BOBIER, Director, Global Process Design and Manufacturing Technology, PolyPeptide Group
Christelle Bobier is the Global Director of Process Design at PolyPeptide Group. She holds a Master’s degree in Chemical Engineering from ENSIC – Institut National Polytechnique de Lorraine (France), obtained in 1998. She began her career at Novasep Process, where she held an engineering leadership role focused on developing and implementing purification processes for pharmaceutical applications.
Christelle joined PolyPeptide Group in 2015 as Global Director of Engineering, contributing to major global investment and capacity expansion projects across the Group. Her role has included hands‑on involvement in industrial transformation initiatives, supported by international experience gained while living and working in Sweden and California. She has extensive expertise in large‑scale solid‑phase peptide synthesis (SPPS), process intensification and purification strategies, with a strong focus on translating innovative concepts into robust and scalable manufacturing platforms.
Message Presenter
Olof Persson, Global Process Design Engineer, PolyPeptide Group
Olof Persson is a Chemical Engineer specializing in Plant and Process Design for the pharmaceutical industry. He has extensive expertise in front‑end engineering as well as concept and basic design of production plants and manufacturing lines. Throughout his career, Olof has built strong hands‑on experience in process design, working on multidisciplinary investment projects across both pharmaceutical and chemical process industries. His core strengths lie in applying deep technical knowledge to deliver robust, high‑quality designs that meet GMP requirements, ensuring reliable execution of manufacturing processes and clean utilities. Driven by a strong commitment to innovation, precision and risk mitigation, Olof focuses on delivering solutions that enhance operational efficiency, product quality and regulatory compliance.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Process Development, Manufacturing and Technology leaders
- Engineering, Process Design and Facilities teams
- CDMO and pharmaceutical decision‑makers
- R&D and CMC professionals
- Innovation, automation and sustainability stakeholders
What You Will Learn
Attendees will learn:
- How modular process and facility design enable flexible, scalable peptide manufacturing, allowing standardized production modules to be configured and replicated according to peptide complexity, synthesis strategy and volume evolution
- How a modular “scale‑out” approach reduces technical and investment risk, shortens expansion timelines and improves asset utilization compared with traditional large, fixed manufacturing units
- How modular architectures support continuous innovation, enabling the progressive integration of new technologies such as process intensification, automation, green chemistry solutions and advanced containment without disrupting existing operations
- Real‑world lessons from the modular expansion of a site in Malmö, illustrating how modular manufacturing simplifies technology transfer, accelerates time to market and builds long‑term resilience for peptide pharma manufacturing platforms
Xtalks Partner
PolyPeptide
PolyPeptide Group is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account